JPT2 and esophageal squamous cell carcinoma: Hence, HN1L/AP-2γ/PLK1/CCND1-SLUG signaling axis drives ESCC progression and chemotherapy resistance, suggesting that blocking PLK1 may attenuate the oncogenic role of HN1L.